Why has Tempus (TEM) dropped by 8.9% since the last earnings report?
Tempus AI (TEM) has seen its stock price drop by 8.9% since the latest earnings report. This decline has put it behind the S&P 500, leaving investors wondering if this downward trend will persist leading up to the next earnings release or if a turnaround is on the horizon. To better understand the recent performance of Tempus AI, let’s examine key highlights from its most recent earnings report, as well as how investors and analysts have reacted to this information.
In the third quarter of 2025, Tempus AI reported impressive results. The company saw a revenue of $334.2 million, marking an 84.7% increase compared to the previous year. Gross profit also saw a significant rise to $209.9 million, up by 98.4% year over year. However, despite the positive revenue and profit growth, Tempus AI reported a wider GAAP net loss of $80.0 million, reflecting a 5.5% increase compared to the previous year. Adjusted EBITDA, on the other hand, improved to $1.5 million from a loss of ($21.8) million in the same quarter of 2024.
Breaking down the revenue streams, Tempus AI saw significant growth in its genomics segment, with revenues doubling year over year. Oncology testing revenue reached $139.5 million, up by 31.7%, while hereditary testing revenue was $102.6 million, marking a 32.8% increase on a pro forma basis. Data and services revenue also showed healthy growth, reaching $81.3 million, up by 26.1% with Insights growing by 37.6%. The company delivered a total of 217,000 clinical tests in the third quarter, reflecting a 33% increase year over year.
Despite the positive revenue growth, Tempus AI reported an adjusted loss of 11 cents per share, surpassing the Zacks Consensus Estimate by 31.3%. Additionally, the company’s stock price saw a decline of 8.9% since the earnings report was released.
Looking ahead, Tempus AI has raised its guidance for 2025, with expected revenues of approximately $1.265 billion for the year. This represents nearly 80% annual growth for the consolidated Tempus and Ambry Genetics businesses. The company also anticipates an Adjusted EBITDA of approximately $20 million for the fourth quarter of 2025, with a slightly positive full-year projection, taking into account the impact of the Paige acquisition.
Overall, Tempus AI’s recent earnings report has showcased significant revenue growth and positive momentum in several key areas. While the stock price has dipped following the report, the company’s strong performance and optimistic outlook for the future provide investors with confidence in its long-term potential.